Can I start an angiotensin receptor neprilysin inhibitor (ARNI) in heart failure with preserved ejection fraction (HFpEF)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, you can start ARNI in HFpEF, particularly in specific patient subgroups

ARNI (sacubitril-valsartan) is now recommended for HFpEF (or HFnrEF, as termed in the most recent Canadian guidelines), with the strongest evidence supporting its use in patients with lower-range ejection fractions (45-57%), women, and those with elevated natriuretic peptides. 1

Evidence-Based Recommendation

The 2025 Canadian Cardiovascular Society guidelines explicitly include ARNI as a Tier 1 treatment option for heart failure with nonreduced ejection fraction (HFnrEF, which consolidates HFmrEF and HFpEF into LVEF >40%). 1 This represents the most current guideline position and supersedes older recommendations that were more cautious about ARNI use in this population.

Starting Dose and Titration

  • Initial dose: 24/26 mg or 49/51 mg twice daily
  • Target dose: 97/103 mg twice daily 1

Key Clinical Trial Evidence

The PARAGON-HF trial 2 enrolled 4,822 patients with HF and EF ≥45% and showed:

  • The primary composite outcome (HF hospitalization + CV death) narrowly missed statistical significance (rate ratio 0.87,95% CI 0.75-1.01, p=0.06)
  • However, important subgroup analyses revealed heterogeneity of treatment effect:
    • Greater benefit in patients with lower EF range (45-57%)
    • Greater benefit in women
    • Reduced total HF hospitalizations (rate ratio 0.85)
    • Improved NYHA class (odds ratio 1.45)
    • Better preservation of renal function
    • Small but significant improvement in quality of life (KCCQ score)

Who Benefits Most?

Based on meta-analysis 3 and subgroup data, ARNI provides the greatest benefit in HFpEF patients with:

  • EF in the 45-57% range (lower end of preserved spectrum)
  • Female sex
  • Elevated systolic blood pressure (predictor of renal outcomes)
  • Elevated NT-proBNP or BNP
  • Reduced baseline renal function (eGFR predictor of mortality benefit)
  • Higher BMI (predictor of CV mortality reduction)

Safety Considerations

Common adverse effects requiring monitoring:

  • Symptomatic hypotension (RR 1.54 vs. ACEi/ARB) - most common titration-limiting factor 3, 2
  • Angioedema (similar rate to ACEi)
  • Lower risk of hyperkalemia compared to ACEi/ARB 2
  • Lower risk of worsening renal function compared to valsartan alone 2

Critical Safety Rule

Maintain at least 36 hours washout period when switching from ACEi to ARNI to minimize angioedema risk 4

Practical Implementation Algorithm

  1. Confirm HFpEF diagnosis: LVEF >40%, elevated natriuretic peptides, structural heart disease
  2. Assess for favorable characteristics: EF 45-57%, female, elevated BP, elevated NT-proBNP
  3. Check contraindications: History of angioedema, symptomatic hypotension, pregnancy
  4. If switching from ACEi: Wait 36 hours minimum
  5. Start low dose: 24/26 mg or 49/51 mg twice daily based on BP tolerance
  6. Titrate every 2-4 weeks to target dose 97/103 mg twice daily as tolerated
  7. Monitor: BP (especially symptomatic hypotension), renal function, potassium

Integration with Other HFpEF Therapies

The Canadian guidelines position ARNI as Tier 1 therapy alongside SGLT2 inhibitors (which have stronger universal evidence in HFpEF). 1 The sequence of initiation should be individualized, but SGLT2i (empagliflozin or dapagliflozin) have more robust outcome data across the entire HFpEF spectrum and may be preferred as first-line therapy, with ARNI added in appropriate phenotypes.

Common Pitfall to Avoid

Don't dismiss ARNI in HFpEF based solely on the PARAGON-HF primary endpoint missing statistical significance. The totality of evidence shows meaningful benefits in specific subgroups, particularly those with EF closer to 45% and women. The 2025 guidelines reflect this nuanced understanding by including ARNI as an evidence-based option. 1

Related Questions

What heart failure medications can be prescribed for a patient who is allergic to angiotensin receptor blockers (ARBs)?
Can discontinuation of an angiotensin-receptor blocker cause heart failure in patients who have never had heart failure?
For a patient with an ejection fraction of 45–50%, should spironolactone or dapagliflozin (Farxiga) be started first?
What is the recommended initial dose, titration schedule, target dose, monitoring parameters, and contraindications for using enalapril in an adult with systolic (reduced‑ejection‑fraction) heart failure?
What are the indications, dosing, monitoring, contraindications, and adverse effects of angiotensin‑converting enzyme (ACE) inhibitors for hypertension, heart failure with reduced ejection fraction, post‑myocardial infarction remodeling, and diabetic nephropathy, and what alternatives can be used if they are not tolerated?
Which diabetes medications are contraindicated in patients with liver cancer, particularly those with significant hepatic impairment (e.g., Child‑Pugh class B or C)?
What is the recommended postoperative management for a patient with esophageal squamous cell carcinoma who has undergone curative primary esophagectomy and resection of a solitary liver metastasis?
In leptospirosis, what is the significance of an elevated serum creatine kinase and how should it be monitored and managed, including antimicrobial therapy and supportive care?
After surgical resection of a T3 N0 M1 esophageal carcinoma with liver metastasis, what is the recommended next step in management?
What is the optimal medical management for an adult patient with moderate aortic stenosis and mild aortic regurgitation?
What is the appropriate management for a patient with metastatic esophageal cancer?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.